Literature DB >> 23074242

Regulation of GPR119 receptor activity with endocannabinoid-like lipids.

Samreen K Syed1, Hai Hoang Bui, Lisa S Beavers, Thomas B Farb, James Ficorilli, Amy K Chesterfield, Ming-Shang Kuo, Krister Bokvist, David G Barrett, Alexander M Efanov.   

Abstract

The GPR119 receptor plays an important role in the secretion of incretin hormones in response to nutrient consumption. We have studied the ability of an array of naturally occurring endocannabinoid-like lipids to activate GPR119 and have identified several lipid receptor agonists. The most potent receptor agonists identified were three N-acylethanolamines: oleoylethanolamine (OEA), palmitoleoylethanolamine, and linoleylethanolamine (LEA), all of which displayed similar potency in activating GPR119. Another lipid, 2-oleoylglycerol (2-OG), also activated GPR119 receptor but with significantly lower potency. Endogenous levels of endocannabinoid-like lipids were measured in intestine in fasted and refed mice. Of the lipid GPR119 agonists studied, the intestinal levels of only OEA, LEA, and 2-OG increased significantly upon refeeding. Intestinal levels of OEA and LEA in the fasted mice were low. In the fed state, OEA levels only moderately increased, whereas LEA levels rose drastically. 2-OG was the most abundant of the three GPR119 agonists in intestine, and its levels were radically elevated in fed mice. Our data suggest that, in lean mice, 2-OG and LEA may serve as physiologically relevant endogenous GPR119 agonists that mediate receptor activation upon nutrient uptake.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23074242     DOI: 10.1152/ajpendo.00269.2012

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  40 in total

1.  Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.

Authors:  Jinjoo Kim; Kumsun Cho; Joo Sung Kim; Hyun Chae Jung; Bumsik Kim; Myeong Soo Park; Geun Eog Ji; Joo-Youn Cho; Kyoung Sup Hong
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

Review 2.  Endocannabinoid signaling pathways: beyond CB1R and CB2R.

Authors:  Roger Gregory Biringer
Journal:  J Cell Commun Signal       Date:  2021-05-12       Impact factor: 5.782

Review 3.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 4.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 5.  Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

6.  Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs.

Authors:  Antoni Pastor; Magí Farré; Montserrat Fitó; Fernando Fernandez-Aranda; Rafael de la Torre
Journal:  J Lipid Res       Date:  2014-03-07       Impact factor: 5.922

7.  Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling.

Authors:  Claudia Manca; Besma Boubertakh; Nadine Leblanc; Thomas Deschênes; Sebastien Lacroix; Cyril Martin; Alain Houde; Alain Veilleux; Nicolas Flamand; Giulio G Muccioli; Frédéric Raymond; Patrice D Cani; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  J Lipid Res       Date:  2019-11-05       Impact factor: 5.922

Review 8.  Gut microbiota and GLP-1.

Authors:  Amandine Everard; Patrice D Cani
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

9.  Structural equation modeling of food craving across the menstrual cycle using behavioral, neuroendocrine, and metabolic factors.

Authors:  Sridevi Krishnan; Karan Agrawal; Rebecca R Tryon; Lucas C Welch; William F Horn; John W Newman; Nancy L Keim
Journal:  Physiol Behav       Date:  2018-07-18

10.  Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.

Authors:  Zhongyi Chen; Lilu Guo; Yongqin Zhang; Rosemary L Walzem; Julie S Pendergast; Richard L Printz; Lindsey C Morris; Elena Matafonova; Xavier Stien; Li Kang; Denis Coulon; Owen P McGuinness; Kevin D Niswender; Sean S Davies
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.